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The antiparasitic drug ivermectin is a novel FXR
ligand that regulates metabolism
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Farnesoid X receptor (FXR) has important roles in maintaining bile acid and cholesterol
homeostasis. Here we report that the antiparasitic drug ivermectin is a ligand for nuclear FXR.
We identify ivermectin using a high-throughput compound library screening and show that it
induces the transcriptional activity of the FXR with distinctive properties in modulating cor-
egulator recruitment. The crystal structure of ivermectin complexed with the ligand-binding
domain of FXR reveals a unique binding mode of ivermectin in the FXR ligand-binding pocket,
including the highly dynamic AF-2 helix and an expanded ligand-binding pocket. Treatment of
wild-type mice, but not of FXR-null mice, with ivermectin decreases serum glucose and
cholesterol levels, suggesting that ivermectin regulates metabolism through FXR. Our results
establish FXR as the first mammalian protein targeted by ivermectin with high selectivity.
Considering that ivermectin is a widely used clinical drug, our findings reveal a safe template
for the design of novel FXR ligands.
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I
vermectin (Stromectol or Ivomec) is a macrocyclic lactone
derived from avermectin, which is produced by an actinomy-
cete, Streptomyces avermitilis1. As a clinical drug against a
variety of nematode and arthropod parasites through the
mediation of neurotransmission, ivermectin is widely used for
the treatment and control of human filarial infections and parasites
in livestock2. It is highly effective and safe, and is well tolerated
with a single annual oral dose in human. The binding of ivermectin
to g-aminobutyric acid receptors increases the releasing of
inhibitory neurotransmitter g-aminobutyric acid in parasite,
resulting in the blocking of the transmission of nerve signals,
which leads to nerve palsy, loss of contractility of the muscle cells
and, ultimately, parasite death3–6. Recently, Hibbs et al.7 provided
the first intuitive evidence for ivermectin to act in parasite by
solving the crystal structure of the glutamate-gated Cl channel
receptor binding to ivermectin. As a drug targeting nematode and
arthropod parasites, ivermectin has not been reported to directly
interact with any mammalian proteins with high selectivity.
Farnesoid X receptor (FXR), also known as bile acid receptor, is
a member of the nuclear hormone receptor superfamily that is
highly expressed in mammalian liver, intestine, kidney and
adrenal gland8–10. Following the ligand binding, the
transcriptional function of FXR is mediated through the
recruitment or release of specific coregulators, including
coactivators such as SRC1 and corepressors such as NCoR and
SMRT11–13. FXR has important roles in maintaining bile acid and
cholesterol homeostasis by regulating genes, such as cholesterol
7a-hydroxylase (CYP7A1)14–16. In recent years, increasing
evidence showed that activation of FXR by agonists, such as
bile acids and GW4064, also had critical roles in regulating
glucose homeostasis and insulin sensitivity17–22. Activation of
FXR by agonists or hepatic overexpression of constitutively active
FXR lowered blood glucose levels in both diabetic db/db
and high-fat diet-fed wild-type mice by downregulating the
critical enzymes involved in gluconeogenesis, such as
phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-
phosphatase (G6Pase). Consistently, FXR-null mice exhibited
glucose intolerance and insulin insensitivity22.
Despite the considerable attention of FXR as a key regulator in
metabolism, the therapeutic potentials of FXR ligands remain to
be further studied16,23. As a natural FXR ligand, bile acid
chenodeoxycholic acid (CDCA) binds to FXR with only
micromolar affinity, and has potential risks of cell toxicity at
concentrations above 100 mM (ref. 13). Further, bile acids also
activate other nuclear receptor, such as VDR and pregnane X
receptor (PXR), as well as TGR5 membrane receptor13. As such,
CDCA is an FXR ligand with poor selectivity and low affinity.
Many synthetic FXR ligands have also been described, but have
limitations owing to side effects and uncertain bioavailability. For
example, GW4064, the most widely used synthetic FXR ligand,
shows ambiguous results in regulating glucose homeostasis16.
Therefore, a new drug-design strategy will be of great use for
developing novel FXR ligands with therapeutic potentials in
treating metabolic syndrome.
In this study we report the identification of nuclear receptor
FXR as a novel target for ivermectin, an antiparasitic drug. Both
the transactivation and binding assays suggest that ivermectin is a
highly selective FXR ligand with unique properties in modulating
coregulator recruitment. The structure of FXR complexed with
ivermectin shows a unique binding mode of ivermectin in the
FXR ligand-binding pocket. Remarkably, ivermectin displays
antidiabetic activities by reducing blood glucose and cholesterol
levels, and also by improving insulin sensitivity in an FXR-
dependent manner. Our observations therefore indicate that
ivermectin may represent a unique safe approach for designing
novel FXR ligands for the therapeutic purpose.
Results
Identification of ivermectin as a novel FXR ligand. To identify
new FXR agonists from the safe drugs on the market, we screened
Biomol FDA (Food and Drug Administration) chemical libraries
based on AlphaScreen biochemical assay, which is widely used for
detecting ligand-dependent interaction between nuclear receptors
and their coactivators24,25. To our surprise, ivermectin, a widely
used antiparasitic drug with a chemical structure distinct from
FXR ligands GW4064 and CDCA, strongly promoted the
coactivator recruitment by FXR (Supplementary Fig. S1). As
shown in Fig. 1a, ivermectin enhanced the interaction of FXR
with various coactivator LXXLL motifs from the family of steroid
receptor coactivators (SRC1-2, SRC2-3 and SRC3-3), with a less
extent than that of GW4064 (Fig. 1a). Notably, ivermectin also
induced the recruitment of corepressor NCoR-2 by FXR, which is
distinct from GW4064 (Fig. 1a). The ability of ivermectin
to induce the recruitment of corepressor NCoR-2 by FXR was
further validated by mammalian two-hybrid assays
(Supplementary Fig. S2). We also performed peptide-profiling
experiments using a panel of 16 unlabelled peptides
(Supplementary Table S3) selected from both coactivators and
corepressors to compete off the binding of the second LXXLL
motif of SRC1 (SRC1-2) to FXR in response to ivermectin
binding (Supplementary Fig. S3). Consistent with the results
above, corepressor motifs, including SMRT-2 and NCoR-2,
substantially inhibited the SRC1 binding to ivermectin-bound
FXR but not GW4064-bound FXR, whereas most coactivator
LXXLL motifs have similar peptide profiles for both ligands. Our
results suggest a partial agonist nature of ivermectin with unique
properties in modulating coregulator recruitment.
To probe the physiological roles of ivermectin in FXR
signalling, cell-based reporter assay was employed to characterize
the transcriptional properties of FXR in response to ivermectin.
COS-7 cells were cotransfected with plasmids encoding full-
length FXRa and other nuclear receptors, respectively, together
with their cognate response reporters. In agreement with initial
library screen results, ivermectin significantly transactivated FXR
using an EcRE reporter, with a weaker activity than GW4064, but
had no substantial impact on other nuclear receptors tested,
including peroxisome proliferator-activated receptor-a, -d and -g,
progesterone receptor, PXR, constitutive androstane receptor,
retinoic acid receptor (RAR) -a and -b, and retinoic acid-related
receptor-a, -b and -g (Fig. 1b). The FXR-specific transactivation
by ivermectin was further validated by mammalian two-hybrid
assays (Supplementary Fig. S4). Of note, ivermectin had a
minimal effect on glucocorticoid receptor (GR) full length but not
GR ligand-binding domain (LBD) (Fig. 1b and Supplementary
Fig. S4). Furthermore, full-dose curves revealed that ivermectin
activated FXR in a concentration-dependent manner with an
EC50 of B200 nM (Fig. 1c), suggesting that ivermectin is a highly
potent FXR ligand. The functional properties of ivermectin to
activate FXR with four different FXR response elements26, in
addition to EcRE, were also analysed and similar results were
obtained (Supplementary Fig. S5).
Structure of the FXR LBD in complex with ivermectin. To
determine the molecular basis for the recognition of FXR by
ivermectin, we solved the crystal structure of FXR LBD com-
plexed with ivermectin. The data statistics and the refined
structures are summarized in Supplementary Table S1. The
structure reveals that the ivermectin-bound FXR LBD adopts a
three-layer helical sandwich arrangement that resembles most
nuclear receptor structures (Fig. 2a)27,28. Notably, carboxy
terminal AF-2 helix is invisible due to very low and ambiguous
electron density, suggesting a highly flexible and dynamic nature
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of AF-2 helix induced by ivermectin binding (Fig. 2a and
Fig. 3a,b), which is consistent with its relatively weaker induction
on FXR transcriptional activity and coactivator recruitment
compared with GW4064. Inside the ligand-binding pocket of
FXR, the existence of ivermectin was apparent from the highly
revealing electron density map shown in Fig. 2b. Superposition of
structures of FXR/ivermectin and FXR/GW4064 (ref. 29) revealed
that both ligand-bound FXR LBDs aligned well with ligands
occupying the similar binding site in the FXR pocket (Fig. 3).
However, both helix 2 and helix 6 were shifted outward and also
distorted to make extra space to accommodate the larger size of
ivermectin, resulting in the substantial expansion of the pocket
size in comparison with GW4064-bound FXR LBD (Fig. 3c). The








Figure 2 | Structural determination of the FXR LBD in complex with ivermectin. (a) The structure of ivermectin bound with FXR LBD in ribbon
representation. FXR LBD is coloured in green and the NCoR-2 motif is in blue. The bound ivermectin is shown in stick representation with carbon and
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Figure 1 | Identification of ivermectin as a novel FXR ligand. (a) Various coregulator binding motifs bind to FXR in response to 0.5mM ivermectin or
GW4064 by AlphaScreen assay. The peptide sequences are listed in Methods. (b) Receptor-specific transactivation by ivermectin. COS-7 cells were
cotransfected with plasmids encoding full-length nuclear receptors and their cognate response reporters, respectively (see Methods). After transfection,
cells were treated with dimethyl sulphoxide (DMSO), 0.5 mM ivermectin or ligands specific for each receptor: FXR, 0.5 mM GW4064; peroxisome
proliferator-activated receptor (PPAR)a, 1mM GW590735; PPARd, 1mM GW0472; PPARg, 1mM rosiglitazone; GR, 0.1 mM dexamethasone; progesterone
receptor (PR), 0.1 mM progesterone; RARa and RARb, 1mM all-trans-retinoic acid; PXR, 10 mM rifampicin; constitutive androstane receptor (CAR), 5 mM
CITCO. (c) Dose responses of ivermectin in transactivating FXR. COS-7 cells were cotransfected with full-length FXRa and an EcRE luciferase reporter.
After transfection for 5 h, cells were treated with various concentrations of ivermectin or GW4064. For b and c, luciferase data were normalized to renilla
activity cotransfected as an internal control. Values are the means±s.e.m. of three independent experiments.
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indicate that FXR has a great flexibility to adapt to the binding of
diverse ligands.
Functional correlation of the ivermectin–FXR interaction. To
validate the roles of pocket residues in ivermectin binding and
FXR activation, we mutated several key residues that contact
different groups of ivermectin and tested the transcriptional
activity of these mutated FXR in response to ivermectin in cell-
based reporter assays using full-length FXR and the EcRE
reporter. A291W mutation was designed to reduce the size of the
FXR pocket by changing the corresponding residue to a trypto-
phan (Fig. 4 and Supplementary Fig. S6A), thereby preventing the
binding of the bulky FXR ligands. As expected, this mutation
abolished the FXR transcriptional activity by both GW4064 and
ivermectin (Fig. 4e. The hydrophobic side chain of F284 stabilizes
the ligand binding by making hydrophobic interactions with both
GW4064 and ivermectin. Despite the loss of hydrophobic con-
tacts with both ligands, F284H mutation was predicted to initiate
hydrogen bonds with a nitrogen atom on GW4064 but not
ivermectin (Fig. 4b and Supplementary Fig. S6B). Accordingly,
this mutant abolished ivermectin-mediated FXR transcriptional
activity but retained the ability to be activated by GW4064
(Fig. 4e). Consistent with Fig. 4e, AlphaScreen assays showed that
the F284H mutant substantially disrupted the binding of the
NCoR-2 peptide and also the SRC1-2 peptide in response to
ivermectin (Supplementary Fig. S6E), further affirming that the
FXR ligand-binding pocket has unique properties that dictate the
discrimination between ivermectin and GW4064. In contrast,
mutations on L287 and H447 (Fig. 4c,d and Supplementary
Fig. S6C,D) abolished or substantially reduced GW4064-mediated
FXR transcriptional activity, but they increased the ability to be
activated by ivermectin (Fig. 4e). Taken together, our mutagenic
analyses showed distinct results on the activation of FXR by
ivermectin and GW4064, highlighting the differential roles of
FXR pocket residues in recognizing various ligands.
Metabolic effects of ivermectin in mice on a high-fat diet. To
investigate whether ivermectin has effects on glucose and cho-
lesterol metabolism in vivo as a FXR ligand, wild-type and FXR–/–
mice were fed with high-fat diet and intraperitoneally (i.p.)
injected daily with vehicle or ivermectin for 14 days. Of note, no
liver injury of ivermectin treatment was observed when evaluated
by aspartate aminotransferase, alanine aminotransferase and liver
histology (Supplementary Fig. S7), in consistency with published
results30,31. Interestingly, serum glucose and cholesterol,
including high-density lipoprotein and low-density lipoprotein
(LDL)/very LDL levels, were significantly decreased in wild-type
mice after treatment with ivermectin (Fig. 5 and Supplementary
Fig. S8), whereas ivermectin treatment had no effect on food
intake and body weight (Fig. 5a,b). In contrast, no significant
differences of serum glucose and cholesterol levels were observed
by ivermectin treatment in FXR–/– mice. Notably, the serum
insulin level was significantly decreased in ivermectin-treated














Figure 3 | Conformational changes of FXR LBD induced by ivermectin binding. (a–c) Superposition of the FXR–ivermectin structure (FXR is in green
and NCoR-2 motif is in blue ) with the FXR–GW4064 structure (FXR is in salmon red and the SRC1 peptide is in cyan), showing the destabilization
of helix12 (a,b) and the pocket size expansion (c) characterized by the conformational changes of helix 2 and helix 6 induced by the binding of ivermectin
(indicated by arrows). Ivermectin is in yellow and GW4064 is in purple. (d) Superposition of ivermectin (yellow) with GW4064 (purple).
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lowered the serum glucose levels through improving insulin
sensitivity. Indeed, ivermectin-injected mice showed improved
insulin sensitivity as well as glucose tolerance compared with
vehicle-treated controls (Supplementary Fig. S9). We conclude
that ivermectin is capable of regulating serum glucose and
cholesterol levels by directly targeting FXR.
To further assess the molecular mechanisms underlying the
physiological functions of ivermectin, we measured the mRNA
levels of metabolism-related genes in liver tissues of mice treated
with either vehicle or ivermectin (Fig. 5f). Data from quantitative
PCR revealed that ivermectin treatment induced hepatic mRNA
levels of SHP, while it reduced the mRNA levels of CYP7A1 and
CYP8B1, three well-characterized FXR direct or indirect target
genes, in wild-type but not FXR–/– mice, reaffirming that
ivermectin is an FXR ligand in vivo. Consistent with the
metabolic benefits of ivermectin, the expression of PEPCK and
G6Pase, two critical enzymes involved in gluconeogenesis, was
significantly reduced in ivermectin-treated wild-type mice, but
not in FXR–/– mice (Fig. 5f), also in agreement with the previous
reports that FXR agonist cholic acid suppressed PEPCK and
G6Pase gene expression through FXR (ref. 21). In contrast to
GW4064, ivermectin showed no significant inhibition of L-PK
mRNA levels in both primary hepatocytes and liver tissues
(Fig. 6f and Supplementary Fig. S10), the regulation associated
with the ambiguous effects of GW4064 on glucose
metabolism16,32. Genes associated with cholesterol metabolism
were also regulated by ivermectin treatment (Fig. 5f). The mRNA
levels of the class B, type-I scavenger receptor, the bile salt
excretory pump and the multidrug resistance gene 2 were all
induced in the liver tissues in ivermectin-treated wild-type but
not FXR / mice (Fig. 5f). Meanwhile, the rate-limiting
enzymes of cholesterol biosynthesis, hydroxymethylglutaryl
coenzyme A synthase and hydroxymethylglutaryl coenzyme A
reductase33,34, were significantly downregulated by ivermectin,
also in an FXR-dependent manner (Fig. 5f). These results reaffirm
that ivermectin regulates gene expression, and glucose and
cholesterol homeostasis in an FXR-dependent manner.
Metabolic effects of ivermectin in diabetic KK-Ay mice. To
further study whether ivermectin treatment improves hypergly-
cemia and hyperlipidemia in a diabetic mouse model as an FXR
ligand, KK-Ay mice were fed with high-fat diet and i.p. injected
daily with vehicle, GW4064 or ivermectin. GW4064 and iver-
mectin treatment had no effect on food intake (Fig. 6a), whereas
ivermectin treatment reduced KK-Ay body weight compared with
vehicle and GW4064 treatment (Fig. 6b). Both GW4064 and
ivermectin significantly lowered serum cholesterol levels (Fig.6c).
Consistent with the results on wild-type mice, ivermectin treat-
ment displayed similar metabolic impact on serum glucose and
insulin levels in diabetic KK-Ay mice (Figs. 6d,e). In contrast,
GW4064 showed little effect.
To assess whether gene expression in KK-Ay mice were
affected by ivermectin treatment, we analysed genes related with
glucose and cholesterol metabolism (Fig. 6f). As expected,
CYP7A1 and CYP8B1 were reduced by GW4064 and ivermectin
treatment. Furthermore, ivermectin treatment elicited either no
induction or significant suppression of the mRNA levels of genes
involved in cholesterol synthesis, such as FDFT1 (farnesyl-
diphosphate farnesyltransferase 1), hydroxymethylglutaryl coen-
zyme A synthase, LDL receptor and hydroxymethylglutaryl
coenzyme A reductase (Fig. 6f), which is also in contrast to the
results from GW4064. In addition, ivermectin also showed more
favourable regulations on G6Pase and PEPCK than on GW4064
(Fig. 6f). Together, these results demonstrated that ivermectin can
effectively improve hyperglycemia and hyperlipidemia in diabetes
model mice by regulating genes expression, with potential
advantages over GW4064 in improving hyperglycemia and
hypercholesterolemia as an FXR ligand.
Discussion
The nuclear receptors are important drug targets due to their
regulation functions in physiological and also pathological
processes. Given the important roles of FXR in a variety of
physiological and pathological processes, the ligands that regulate
FXR activity are promising therapeutic agents for different
































Figure 4 | Functional correlation of the ivermectin/FXR interactions.
(a–d) Molecular determinants of the interaction between FXR with ligand
ivermectin. Overlays of the FXR–ivermectin structure (green) with the FXR–
GW4064 (salmon red) structure, where ligand ivermectin is in yellow and
GW4064 is in purple. The hydrophobic interactions and hydrogen bonds
are shown with lines and arrows, respectively. The potential hydrophobic
interactions and hydrogen bonds, if the corresponding mutations are made
as indicated in e, are shown in dashed lines and dashed arrows,
respectively. (e) Differential effects of mutations of key FXR residues on its
transcriptional activity in response to ivermectin and GW4064 in cell-
based reporter assays. COS-7 cells were cotransfected with plasmids
encoding full-length wild-type (WT) FXR or FXR mutants as indicated in the
figure, together with an EcRE luciferase reporter. The cells were treated with
0.5mM ivermectin and GW4064, respectively. The dashed line indicates
the activation level of WT FXR by ivermectin. Values are the means±s.e.m.
of three independent experiments. *Po0.05, **Po0.01 versus vehicle,
Student’s t-test.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2924 ARTICLE
NATURE COMMUNICATIONS | 4:1937 | DOI: 10.1038/ncomms2924 | www.nature.com/naturecommunications 5
& 2013 Macmillan Publishers Limited. All rights reserved.
clinical applications of FXR ligands remain much less developed. We
describe here the identification and characterization of ivermectin as
a unique FXR ligand (Fig. 1). Ivermectin binds in the pocket of FXR
with a distinctive binding mode owing to its distinct molecular size
and structure compared with other ligands (Fig. 2, and Figs 3 and 4),
such as GW4064 (ref. 29), fexaramine35 and CDCA36, which
provides another evidence for the conformational flexibility of
nuclear receptors to adapt diverse ligands.
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Figure 5 | Ivermectin regulates metabolic parameters in a FXR-dependent manner. Wild-type (WT) and FXR / (knock-out (KO)) mice were fed
with high-fat diet and i.p. injected with vehicle or ivermectin (1.3 mg kg 1) once a day for 14 days (n¼6 per group for all data in this figure). The food intake
were measured every second day. (a) Food intake. Kcal, kilocalories; BW, body weight. After 6 h of fasting, mice were weighed and the body weights
were indicated as percentage (%) of the initial weight of mice (b). Serum was collected and the levels of serum glucose (c), insulin (d) and cholesterol
(e) were determined. (f) Hepatic mRNA levels of metabolism-related genes were quantified by real-time PCR and normalized to actin. Values are the
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Figure 6 | Ivermectin treatment improves hyperglycemia and hyperlipidemia in diabetic KK-Ay mice. KK-Ay mice were fed with high-fat diet and i.p.
injected with vehicle, ivermectin (1.3 mg kg 1) or GW4064 (30 mg kg 1) once a day for 14 days (n¼ 6 per group for all data in this figure). The food intake
were measured every second day. (a) Food intake. Kcal, kilocalories; BW, body weight. After 6 h of fasting, mice were weighed and the body weights were
indicated as percentage (%) of the initial weight of mice (b). Serum was collected and serum cholesterol (c), glucose (d) and insulin (e) levels were
determined. (f) Hepatic mRNA levels of metabolism-related genes were quantified by real-time PCR and normalized to actin. Values are the means±s.e.m.
of six independent experiments. *Po0.05, **Po0.01 versus vehicle, Student’s t-test.
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More importantly, ivermectin treatment can downregulate
serum glucose and cholesterol levels by directly targeting FXR
(Figs 5 and 6). Previous reports also showed that activation of
FXR by the synthetic agonist GW4064 or hepatic overexpression
of constitutively active FXR significantly lowered serum glucose
levels in both wild-type mice and diabetic mice models (db/db
and KK-Ay mice) in an FXR-dependent manner by regulating
related genes21,22. However, recent observations of glucose level
regulation by FXR agonist GW4064 remains ambiguous, as some
reports suggested that activation of FXR with GW4064 in wild-
type or diabetic mice did not improve hyperglycemia17,37.
Although the gluconeogenesis gene G6Pase was reduced with
GW4064 treatment in our studies, no effects on serum glucose
and insulin levels were observed. However, our studies
demonstrated much more favourable effects of ivermectin on
glucose and insulin homeostasis in both wild-type and KK-Ay
mice by regulating related genes. Further, our results showed that
ivermectin treatment had no obvious body weight gain, which is a
side effect of GW4064 (ref. 38). Together, our results suggest that
ivermectin as a novel FXR ligand may possess advantages over
GW4064 in regulating glucose homeostasis.
The distinctive functional profile of nuclear receptors in
response of various ligand binding is largely determined by the
selective usage of transcriptional coregulators, as ligand-specific
recruitment of coregulators ultimately controls transcriptional
output of direct and indirect target genes. Thus, ligand-
bound FXR may show diverse pharmacological functions
depending on the specific binding of coregulators induced by
different ligands. The results from both biochemical AlphaSc-
reen assay and cell-based reporter assay showed that ivermectin
is a partial agonist for FXR owing to its much less capability in
recruiting coactivators compared with typical full agonist
GW4064 (Fig. 1). Unlike a typical full agonist, such as
GW4064, ivermectin-bound FXR has a marked binding
preference for the corepressor motifs, including SMRT-2 and
NCoR-2 (Fig. 1a and Supplementary Fig. S2). Consistent with
these results, the crystal structure of the ivermectin/FXR
complex reveals a highly dynamic AF-2 helix, which is critical
for nuclear receptors to interact with coregulators (Fig. 3). Thus,
the selective usage of coregulators may contribute to the unique
characteristics of ivermectin in modulating FXR activity in
metabolism.
Considering that ivermectin is already a clinical drug approved
by the FDA, our findings reveal an alternative template for design
of FXR ligands with therapeutic potentials to rapid clinical
applications by providing a safe lead compound. Moreover, given
the fact that the molecular targets of many FDA drugs are still not
clear39, our study also validates a powerful screening strategy for
the search of novel lead compounds for nuclear receptors as well
as other molecular targets based on existing drugs, which also
opens up many potentials for old drugs.
Methods
Protein preparation. The human FXR LBD (residues 243–472) was expressed as
an amino-terminal 6His fusion protein from the expression vector pET24a
(Novagen). BL21 (DE3) cells transformed with expression plasmids were grown in
lysogeny broth at 25 C to an OD600 of B1.0 and induced with 0.1 mM isopropyl
1-thio-b-D-galactopyranoside at 16 C. Cells were collected and sonicated in 200 ml
extraction buffer (20 mM Tris pH 8.0, 150 mM NaCl, 10% glycerol and 25 mM
imidazole) per 6 l of cells. The lysate was centrifuged at 20,000 r.p.m. for 30 min
and the supernatant was loaded on a 5-ml NiSO4-loaded HiTrap HP column (GE
Healthcare). The column was washed with extraction buffer and the protein was
eluted with a gradient of 25–500 mM imidazole. The FXR LBD was further purified
with a Q-Sepharose column (Amersham Biosciences). To prepare the protein–
ligand complex, we added a fivefold molar excess of the ivermectin to the purified
protein, followed by filter concentration to 10 mg ml 1. The FXR LBD was
complexed with a twofold molar of a NCoR peptide (PASNLGLEDIIRKALMGS)
before filter concentration.
Cofactor binding assays. The binding of the various peptide motifs to FXR LBD
in response to ligands was determined by AlphaScreen assays using a hexahistidine
detection kit from Perkins-Elmer as described before25. The experiments were
conducted with B20–40 nM receptor LBD and 20 nM biotinylated cofactor
peptides in the presence of 5 mg ml 1 donor and acceptor beads in a buffer
containing 50 mM MOPS, 50 mM NaF, 0.05 mM CHAPS and 0.1 mg ml 1 BSA,
all adjusted to pH 7.4.





Crystallization and structure determination. The crystals of FXR/ivermectin
complex were grown at room temperature in hanging drops containing 1.0 ml of the
above ligand–protein solutions and 1.0 ml of well buffer containing 50 mM HEPES
pH 7.0 and 3.5 M sodium formate. The crystals were directly flash-frozen in liquid
nitrogen for data collection. The observed reflections were reduced, merged and
scaled with DENZO and SCALEPACK in the HKL2000 package40. The structures
were determined by molecular replacement in the CCP4 suite. Manual model
building was carried out with Coot41 followed by REFMAC refinement in the
CCP4 suite.
Transient transfection assay. COS-7 cells were maintained in DMEM containing
10% fetal bovine serum and were transiently transfected using Lipofectamine 2000
(Invitrogen)42. All mutant FXR plasmids were created using the Quick-Change
site-directed mutagenesis kit (Stratagene). Before 24 h of transfection, 24-well
plates were plated (5 104 cells per well). The cells were cotransfected with
plasmids encoding full-length nuclear receptors and their cognate luciferase
reporters as follows: human FXRa with EcRE-Luc, human peroxisome proliferator-
activated receptors (a, d and g) with PPRE-Luc; human retinoic acid-related
receptors (a, b and g) with the Pcp2/RORE-Luc; human GR or progesterone
receptor with the MMTV-Luc; human RARa or RARb with bRE-Luc reporter; and
human PXR and constitutive androstane receptor with PBRE-luc reporter. Among
these reporters, MMTV-luc contains one copy of the response elements and the
others have three copies. Ligands were added 5 h after transfection. Cells were
collected 24 h later for the luciferase assays. Luciferase activities were normalized to
renilla activity cotransfected as an internal control.
Animals and diets, or compounds. C57BL/6J, homozygous FXR-deficient
(FXR–/–) mice19 and KK-Ay mice were maintained under environmentally
controlled conditions with free access to standard chow diet and water. Animal
experiments were conducted in the barrier facility of the Laboratory Animal
Center, Xiamen University, approved by the Institutional Animal Use and Care
Committee of Xiamen University, China. Mice of 10–12 weeks of age were fed with
high-fat diet containing 60% fat, 20% protein and 20% carbohydrate (Research
Diets, D12492) and i.p. injected with either vehicle (40% of 2-hydroxypropyl-b-
cyclodextrin, Sigma), or vehicle containing GW4064 (30 mg kg 1, Sigma) or
ivermectin (1.3 mg kg 1) once a day for 14 days. Mice were killed after 6 h of
fasting, mice body were weighed, tissues were collected and frozen in liquid
nitrogen for use, and serum were collected to measure metabolite parameters.
Real-time PCR. RNA was isolated using Tissue RNA kit (Omega Bio-Tek, GA).
The first strand complementary DNA were obtained by TAKARA reverse tran-
scription kit. Real-time quantitative PCR were performed on a CFX96 Real-Time
PCR Detection System (Bio-Rad) using SYBR Premix Ex Taq (TAKARA). Relative
mRNA expression levels were normalized to actin levels. The primers used in this
assay were listed in the Supplementary Table S2.
Quantification of serum biomarkers. Serum was drawn from compound-treated
mice after 6 h fasting. Serum glucose and cholesterol were analysed using glucose
oxidase method (Applygen, Beijing, China) and Cholesterol Assay Kit (Bioassay
Systems, USA), respectively. Serum insulin levels were determined by enzyme-
linked immunosorbent assay using ultra-sensitive mouse insulin kit (Crystal Chem.
Inc., USA).
Statistical analysis. Results were expressed as mean±s.e.m. P-values were
calculated by using Student’s t-test.
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